Instead of preventing the reaction between PD-1 receptors on cytotoxic T-cells and PDL-1 receptors on tumour cells which handicap the immune response, we will engineer the tumour cells so they themselves build proteins that will destroy their own PDL-1 receptors.
We will deliver the engineered gene sequence through liposome nano-particle drug carriers which will efficiently enter the mutated tumour cells and precisely target the diseased area. Liposome nano-carriers are highly biocompatible and non-immunogenic.
The gene sequence introduced into the tumour cells will be used to build proteolysis targeting chimera (PROTAC) molecules designed to break down PDL-1 receptor proteins into smaller polypetides, preventing tumour cells from suppressing the immune system.
Today's immunotherapies require increased dosage with each intake as the drugs which send antibodies inhibiting the PD-1 to PDL-1 reaction wear down over time. On the other hand, genetically modifying the tumour cell's DNA will allow it to continuously create proteins destroying its own PDL-1 receptors, and this information will be passed on to their daughter cells.
Many cancer therapies fall short when delivering their drugs to the affected area. Targeting is not precise enough and often non-selective, which causes buildup and adverse side-effects that severely weaken the body. By using nanoparticles such as liposomes, we can target tumours more efficiently by binding with over-expressed antigens. We can also take advantage of the increased permeability liposomes offer.
Engineering tumour cells to halt their own immunorepressive characteristics is a more sustainable solution possible due to the PROTAC molecule, an emerging therapeutic tool. PROTAC will selectively destroy the PDL-1 receptor proteins of the tumour cells by degrading them into smaller amino acids or polypeptides.
Ayleen is a brain-machine interface researcher and developer, with a passion for neuroscience and Artificial Intelligence.
Ramy is a DApp developer and blockchain enthusiast highly invested into innovation in healthcare.
Abe is a computer vision developer interested in finding intersections between medicine and AI.